
Dabur Red Paste Turns #SwitchToFluorideFree Campaign into Nationwide Brand Movement
New Delhi [India], July 28: Building on the momentum from their #SwitchToFluorideFree campaign, Dabur Red Paste has taken a bold next step in its campaign to raise awareness about excessive fluoride exposure. What began as an eye-opening initiative to spark dialogue has now evolved into a nationwide brand movement, encouraging consumers across India to rethink what's really in their toothpaste and make an informed switch to fluoride-free alternatives, challenging several industry giants in the process.
- The national campaign backed by regional influencer storytelling, animated explainer videos, carousel education posts, SEO, search campaigns & purpose-led positioning aims to redefine oral care advertising.
- To execute this campaign, Dabur Red Paste partnered with creative & digital agency Mixed Route Juice to build a full-funnel campaign.
Every morning, millions of Indian families wake up and reach for the same thing: their toothbrush and toothpaste. It's a habit that starts in early childhood and becomes second nature. But a quiet shift in this routine is underway, driven by growing awareness around one key ingredient found in many toothpastes i.e.fluoride.
Across the world, there has been growing concern about the health risks associated with excessive fluoride exposure. According to fluoridealert.org, international studies have highlighted potential links between high fluoride intake and a range of health issues, including neurotoxicity, particularly in children. These findings have led experts and parents alike to question the long-standing practice of fluoride use in everyday dental products and to seek safer, science-backed alternatives.
And this movement is being led by Dabur Red Paste's recent nationwide public awareness campaign titled #SwitchToFluorideFree, aiming to educate Indian households on the potential risks of excess fluoride exposure, especially through daily oral care products like toothpaste.
The trigger? A recent report by the Ministry of Jal Shakti revealed that groundwater in 370 districts across 23 states in India contains fluoride levels beyond the permissible limit. In regions already consuming high levels of fluoride through water, adding more through fluoridated toothpaste, especially since children tend to accidentally swallow the toothpaste, could elevate long-term health risks, like:
- Dental Fluorosis (white or brown spots on teeth)
- Brittle Bones
- Low IQ
"As a brand that has always believed in offering natural, safe, and effective oral care solutions, we felt it was our responsibility to bring this issue to the forefront." said Mr. Prashant Agarwal, Head of Marketing, Oral Care, Dabur India Ltd."#SwitchToFluorideFree is more than a campaign, it's a public health message, urging families to check their toothpaste labels and make the informed choice towards fluoride-free alternatives like Dabur Red Paste."
What makes the campaign particularly powerful is its hyper-local storytelling approach. Influencers from regions most affected by high fluoride in groundwater, such as Uttar Pradesh (UP), West Bengal, Maharashtra, Telangana, Tamil Nadu and Odisha shared contextualized content about the fluoride report, encouraging viewers to "Flip the Pack" and look for safety instructions like "Do Not Swallow".
The messaging culminates in a key call-to-action: #SwitchToFluorideFree, with Dabur Red Paste positioned as a clinically proven, Ayurvedic, fluoride-free toothpaste that fights 7 dental problems.
To execute this campaign, Dabur Red Paste partnered with creative and digital agency Mixed Route Juice to build a full-scale brand movement combining regional influencer storytelling, animated explainer videos, carousel education posts, search engine optimization (SEO), search campaigns and purpose-led positioning aims to redefine oral care advertising.
"Our goal was to bring empathy and urgency to a silent issue hiding in plain sight." said Amrita Sharma, Founder & Creative Director at Mixed Route Juice. "By combining public data, Ayurveda's relevance, and influencer-led narrative, we made the science accessible and the solution obvious. This is the kind of real, meaningful story-telling that we delight in."
With a 360-degree approach to create mass awareness among the parents and healthcare-conscious consumers, the campaign has gained momentum on the digital and offline platforms.
Dabur Red Paste,being fluoride-free toothpaste offers a safer alternative that doesn't compromise on oral health. It helps prevent tooth decay, reduces gum bleeding, fights bad breath, and alleviates sensitivity, while avoiding the risks associated with excessive fluoride.
As oral care becomes part of the larger conversation around preventive health, #SwitchToFluorideFree marks a timely reminder for Indian families to not just brush, but make the wiser choice and brush better.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Time of India
an hour ago
- Time of India
Gujarat ranks 3rd in sickle cell disease
Ahmedabad: Data tabled in the Lok Sabha on Aug 1 indicated that Gujarat, with 28,178 identified sickle cell disease patients, has the third-largest patient base in the country. Odisha, with 96,484 cases, leads the table, and is followed by Madhya Pradesh with 30,762 cases, according to data shared by Union health minister J P Nadda in response to a question by Rajkumar Raot. What set Gujarat apart was that 90% of the cases (25,282) were recorded among the scheduled tribes (ST), including those in the particularly vulnerable tribal group (PVTG) category, which was the highest among Indian states and significantly higher compared to Odisha and Madhya Pradesh, according to the statistics up to the end of July 2025. You Can Also Check: Ahmedabad AQI | Weather in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad The answer indicated that a total of 77.34 lakh citizens were screened to identify those with the condition. Under the National Sickle Cell Anaemia Elimination Mission (NSCAEM), persons with the condition are provided counselling regarding lifestyle, pre-marriage and pre-natal decisions and nutritional supplements among others. "The condition is marked by abnormal haemoglobin that makes red blood cells rigid and take the shape of a sickle. They often block the blood flow, leading to anaemia," a public health expert said. "Gujarat has recently launched a drive to understand the genetic makeup of the tribal population," the expert added.
&w=3840&q=100)

Business Standard
2 hours ago
- Business Standard
Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26
Ahmedabad-based Eris Lifesciences is looking to target opportunities in the nearly ₹5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced a withdrawal of its insulin products in April this year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to ₹125 crore. Revenue rose to ₹773 crore during the June quarter against ₹720 crore in the year-ago period. 'We expect that Novo's cartridge inventory in the market will run out by October. So this market opportunity is something that one can start monetising from the November-December time frame,' the company's executive director and chief executive officer (CEO) Krishnakumar Vaidyanathan told Business Standard. He added that the timing fits Eris' plans as its Bhopal unit's cartridge filling capability will start getting operational from January. Vial manufacturing has already been commissioned at the Bhopal unit, with the company creating a strategic stock of insulins. This comes at a time when Eris already is the largest domestic player in insulin. The company had last year acquired the India formulations business of Biocon Biologics last year, including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined ₹60 crore in revenue last year. Basalog and Insugen had combined revenues of ₹200 crore at the time of acquisition,' he said. He added that with this, the company's insulin franchise has become really large with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide 1) receptor agonist that is used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of the financial year 2025-26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to market is concerned, the company said it is already in a strong position because of its dominant position in insulins and prior presence in the GLP market with the launch of Liraglutide in September last year.


Economic Times
3 hours ago
- Economic Times
Eris Lifesciences eyes ‘good' share in semaglutide generics, says COO
Mr. Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer Eris Lifesciences looks to leverage its experience in integrated diabetes portfolio to take a lead among the first wave of generic semaglutide anti-diabetic and weight-loss drugs to hit the market early next year, a top official said. The company is looking at a 'good' share of the market, Krishnakumar Vaidyanathan, executive director and chief operating officer of Eris Lifesciences, told ET in an interaction. Semaglutide is the active ingredient in Novo Nordisk's blockbuster drugs Wegovy and Ozempic. Its patent in India will expire in March 2026. 'We are gearing up to be among the first to enter the market post loss of exclusivity,' Vaidyanathan said. 'We expect the overall market for GLP-1 at the end of the first 12 months (after the loss of exclusivity) to be at least 10 million units… And we expect to get a good share of the market.' Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist. Eris Lifesciences' existing diabetes portfolio includes orals, insulin and GLP-1 in the form of liraglutide. Its network of field representatives, patient connect and service platform in this space gives the firm an advantage over others, Vaidyanathan said. 'We do this day in and day out because of insulin. That gives us the confidence that we'll be able to step this up for GLP-1 as well.'Globally, the GLP-1 market is dominated by Eli Lilly and Novo Nordisk, which are also the two biggest insulin companies in the world. 'Being successful and big in the insulin market provides a huge tailwind when it comes to selling GLPs,' Vaidyanathan said. 'We have combined service with technology and product to create a winning combination in insulin and GLP therapy entry is not any different, which also requires a lot of patient education over and above the service on using the pens,' he said. 'We have an integrated diabetes portfolio because we currently sell GLP-1 in the form of liraglutide.' Dr Reddy's Labs, Sun Pharmaceutical Industries, Cipla, Mankind Pharma, Torrent Pharmaceuticals, and Zydus Lifesciences are also among Indian drugmakers readying to launch generic semaglutide next year. Eris Lifesciences launched liraglutide, a once-a-week GLP-1 product, last September. 'We have taken very good market shares in all the other LOE (loss of exclusivity) opportunities that we have seen in diabetes,' Vaidyanathan said. 'We have taken market ranks of 1 to 5 in each one without exception – vildagliptin, sitagliptin, linagliptin, dapagliflozin and empagliflozin. That gives us the confidence that we should be getting a fair share of the market.' Vishal Manchanda, pharma analyst at brokerage Systematix Group, said its full portfolio of anti-diabetes drugs to offer to diabetologist, spanning all oral and injectable options, should give Eris Lifesciences 'a strong positioning in a market where the large pharma majors like Sun, Lupin, Dr Reddy's, Cipla, Mankind and Zydus come in with their dominant brand presence.'